M&A Deal Summary

Global Cord Blood Acquires Cellenkos

On April 29, 2022, Global Cord Blood acquired life science company Cellenkos for 664M USD

Acquisition Highlights
  • This is Global Cord Blood’s 1st transaction in the Life Science sector.
  • This is Global Cord Blood’s largest (disclosed) transaction.
  • This is Global Cord Blood’s 1st transaction in the United States.
  • This is Global Cord Blood’s 1st transaction in Texas.

M&A Deal Summary

Date 2022-04-29
Target Cellenkos
Sector Life Science
Buyer(s) Global Cord Blood
Deal Type Add-on Acquisition
Deal Value 664M USD

Target

Cellenkos

Houston, Texas, United States
Cellenkos is a clinical-stage biotechnology company focused on the development and commercialization of Allogeneic, Tissue-Targeted, Immune T-Regulatory Cell Therapies to Treat Autoimmune Diseases and Inflammatory Disorders. Being derived from umbilical CB. Cellenkos' Tregs are naïve, bonafide suppressor cells that resolve inflammation through multiple direct and indirect interactions. The company utilizes its proprietary CRANETM platform technology to isolate, activate, enrich and expand the tissue-directed CB Treg cells that leverage cellular intelligence to seek, localize, proliferate and resolve tissue inflammation. Cellenkos' in-house cGMP facility allows for large-scale manufacturing where multiple doses can be generated from a single CB unit. These off-the-shelf allogeneic cell products are cryopreserved and are available on-demand for infusion at the point of care. Cellenkos is based in Houston, Texas.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Global Cord Blood

Hong Kong, China

Category Company
Founded 2006
Sector Life Science
Employees1,202
Revenue 1.2B CNY (2022)
DESCRIPTION

Global Cord Blood is a provider of umbilical cord blood storage and ancillary services. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. Global Cord Blood was founded in 2006 and is based in Hong Kong, China.


DEAL STATS #
Overall 2 of 2
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 2 of 2
State (Texas) 1 of 1
Country (United States) 1 of 1
Year (2022) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-06-04 Cordlife Group

Singapore, Singapore

Cordlife Group Ltd. is a healthcare company that provides cord blood and cord lining banking services. Cordlife Group Ltd. was founded in 2001 and is headquartered in Singapore.

Buy -